Forbion Surpasses Target with $2.2B Fundraise, Boosting Biotech Investments

Forbion, a leading European life sciences venture firm, has successfully raised over €2 billion ($2.2 billion) in its latest fundraising effort, surpassing initial targets significantly. The funds, named Forbion Growth Opportunities III and Forbion Ventures VII, are designed to back late-stage biotech companies in North America and Europe, as well as early-stage therapeutics startups[1][2]. This success brings Forbion's total assets under management to over €5 billion and positions the firm to support approximately 30 biotech firms. The firm has seen notable investment exits recently, including acquisitions by major companies such as Johnson & Johnson and Novartis, showcasing Forbion's ability to achieve substantial financial outcomes and societal impact[1][2].